Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A model for gene therapy of human hereditary lymphedema

9 Oct 2001

Abstract excerpt

Primary human lymphedema (Milroy's disease), characterized by a chronic and disfiguring swelling of the extremities, is associated with heterozygous inactivating missense mutations of the gene encoding vascular endothelial growth factor C/D receptor (VEGFR-3). Here, we describe a mouse model and a possible treatment for primary lymphedema. Like the human patients, the lymphedema (Chy) mice have an inactivating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis and VEGF in Cancer
Share to Lymphatic System and Diseases
Share to Sympathectomy and Hyperhidrosis Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 11592985
DOI: 10.1073/pnas.221449198

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A model for gene therapy of human hereditary lymphedemaPMID 11592985Read ↗

Research Perspectives in Inherited Lymphatic DiseaseSemantic proximity Read ↗

Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3.Semantic proximity Read ↗

A novel mutation in the conserved sequence of vascular endothelial growth factor receptor 3 leads to primary lymphoedema.Semantic proximity Read ↗

Phenotypic characterization of primary lymphedema.Semantic proximity Read ↗

Lymphangiogenic Gene Therapy With Minimal Blood Vascular Side EffectsSemantic proximity Read ↗

Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase.Semantic proximity Read ↗

Mutations in the VEGFR3 Signaling Pathway Explain 36% of Familial LymphedemaSemantic proximity Read ↗

Genetics of lymphatic anomalies.Semantic proximity Read ↗

Recessive primary congenital lymphoedema caused by a <i>VEGFR3</i> mutationSemantic proximity Read ↗

Mutation in vascular endothelial growth factor-C, a ligand for vascular endothelial growth factor receptor-3, is associated with autosomal dominant milroy-like primary lymphedema.Semantic proximity Read ↗

Candidate gene analysis in primary lymphedema.Semantic proximity Read ↗

Lymphangiogenesis requires Ang2/Tie/PI3K signaling for VEGFR3 cell-surface expressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.